Investor Presentation of Asarfi Hospital Limited for the Quarter and Financial Year ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Asarfi Hospital Limited reported strong FY26 results with revenue of Rs 173.5 Cr, up 42% YoY, and PAT of Rs 16.7 Cr, up 58% YoY. Q4 FY26 revenue grew 28% YoY to Rs 45 Cr, though EBITDA margin compressed to 17% from 18% in Q4 FY25. The company operates 350 beds across Super-Specialty (285 beds) and Cancer (65 beds) units in Dhanbad, Jharkhand. Key growth drivers include Cardiology (largest revenue contributor) and Orthopaedics (142% YoY growth). The company partnered with Gleneagles Hospital Chennai to establish Jharkhand's first Multi-Organ Transplant Unit. Vision 2028 targets include 500+ beds, Rs 400 Cr revenue, and 23-25% EBITDA margin.
Strong revenue growth and improving PAT margin demonstrate solid operational performance, though near-term margin pressure in Q4 FY26 may concern short-term investors. The strategic partnership and capacity expansion plans signal positive long-term growth potential.